Neurological manifestations in Erdheim-Chester disease: Two case reports;Manifestaciones neurológicas en la enfermedad de Erdheim-Chester: a propósito de 2 casos

Neurologia

Volumn 31, Issue 6, 2016, Pages 426-428

  Rouco, I ^a   Arostegui, J ^a   Canovas A ^a   Gonzalez del Tanago J ^a   Fernandez I ^a   Zarranz, J J ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ARTICLE; ERDHEIM CHESTER DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; AGED; CASE REPORT; COMPLICATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FATALITY; FEMALE; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PATHOPHYSIOLOGY; X-RAY COMPUTED TOMOGRAPHY;

AGED; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ERDHEIM-CHESTER DISEASE; FATAL OUTCOME; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897955743     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2014.01.010     Document Type: Letter

References (13)

1. Haroche, J., Arnaud, L., Amoura, Z., Erdheim-Chester disease. Curr Opin Rheumatol 24 (2012), 53–59.
2. Juanós, M., Selva-O'Callaghan, A., Solanich, J., Vidaller-Palacin, A., Martí, S., Grau, J.M., et al. Enfermedad de Erdheim-Chester: estudio de 12 casos. Med Clín 139 (2012), 398–403.
3. Braiteh, F., Boxrud, C., Esmaeli, B., Kurzrockv, R., Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferón-alpha. Blood 106 (2005), 2992–2994.
4. Arnaud, L., Hervier, B., Neel, A., Hamidou, M., Kahn, J.E., Wechsler, B., et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood 117 (2011), 2778–2782.
5. Janku, F., Amin, H.M., Yang, D., Garrido-Laguna, I., Trent, J.C., Kurzrock, R., Response of histiocytoses to imatinib mesylate: Fire to ashes. J Clin Oncol 28 (2010), 633–636.
6. Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin, N., Renand, A., Galateau-Salle, F., et al. Rationale and efficacy of interleukin-1 in targeting in Erdheim-Chester disease. Blood 116 (2010), 4070–4076.
7. Myra, C., Sloper, L., Tighe, P.J., McIntosh, R.S., Gregson, R.H.S., Sokal, M., et al. Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 88 (2004), 844–847.
8. Haroche, J., Cohen-Aubart, F., Emile, J.F., Arnaud, L., Maksud, P., Charlotte, F., et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121 (2013), 1495–1500.
9. Bianco, F., Iacovelli, E., Tinelli, E., Locuratolo, N., Pauri, F., Fattapposta, F., Characteristic brain MRI appereance of Erdheim-Chester disease. Neurology 73 (2009), 2120–2121.
10. Lachenal, F., Cotton, F., Desmurs-Clavel, H., Haroche, J., Taillia, H., Magy, N., et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: Report of 6 cases and systematic review of the literature. J Neurol 253 (2006), 1267–1277.
11. Arnaud, L., Malek, Z., Archambaud, F., Kas, A., Toledano, D., Drier, A., et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 60 (2009), 3128–3138.
12. Ribeiro, M.J., Idbaih, A., Thomas, C., Remy, P., Martin-Duverneuil, N., Samson, Y., et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis: Results and potential interest for an early diagnosis of the disease. J Neurol 255 (2008), 575–580.
13. Conley, A., Manjila, S., Guan, H., Guthikonda, M., Kupsky, W.J., Mittal, S., Non-Langerhans cell histiocytosis with isolated CNS involvement: An unusual variant of Erdheim-Chester disease. Neuropathology 30 (2010), 634–647.